Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Period	PE Ratio
2018-12-31	N/A
2019-12-31	-0.40
2020-12-31	-0.78
2021-12-31	-0.71
2022-12-31	-0.73
2023-12-31	-0.53
2024-12-31	-0.64

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KZR	$7.38	-0.14%	0.10M
3
4
5

Kezar Life Sciences Inc. (KZR) PE Ratio

PE Ratio Data

Get Kezar Life Sciences Inc. Data in Excel

More KZR Financial Data